z-logo
open-access-imgOpen Access
S173: T‐CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T‐CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Author(s) -
Dekhtiarenko I.,
Lelios I.,
Attig J.,
Sleiman N.,
Lazzaro D.,
Clausen I.,
Gräfe N.,
Helms H.J.,
Schindler E.,
Belli S.,
Fauti T.,
Eckmann J.,
Umana P.,
Jacob W.,
Schneider M.,
Hasselbalch Riley C.,
Hutchings M.,
Yoon S.S.,
Koh Y,
Manier S.,
Facon T.,
Harrison S. J.,
Er J.,
Volzone F.,
Pinto A.,
Montes C.,
Ocio E. M.,
AlfonsoPierola A.,
Rodríguez Otero P.,
Offner F.,
Guidetti A.,
Corradini P.,
Titouan C.,
Hulin C.,
Touzeau C.,
Moreau P.,
Popat R.,
Leong S.,
Mazza R.,
CarloStella C.,
Bröske A.M. E.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843584.56113.c6
Subject(s) - medicine , cd8 , pharmacodynamics , t cell , multiple myeloma , cytokine release syndrome , flow cytometry , pharmacology , antibody , bone marrow , biomarker , oncology , pharmacokinetics , immune system , immunology , chemistry , chimeric antigen receptor , biochemistry

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here